✦ LIBER ✦

Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853)

✍ Scribed by F. Keuppens; P. Whelan; J. L. De Carneiro Moura; D. Newling; A. Bono; L. Denis; M. Robinson; C. Mahler; R. Sylvester; M. De Pauw; K. Vermeylen; P. Ongena; European Organization for Research; Treatment of Cancer–-Genitourinary Group

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 540 KB
Volume: 72
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19931215)72:12+<3863::aid-cncr2820721720>3.0.co;2-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quality-adjusted survival (Q-TWiST) anal

Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: Comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer

✍ Rosendahl, Ingvar; Kiebert, Gwendoline M.; Curran, Desmond; Cole, Bernhard F.; W 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB 👁 1 views

## Background: The first data analysis of the european organization for research and treatment of cancer (eortc) 30853 trial indicated a significantly longer time to progression and duration of survival for the maximal androgen blockade (mab) treatment arm. however, the mab treatment arm had a high

Long-term results of danish prostatic ca

Long-term results of danish prostatic cancer group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer

✍ P. Iversen; F. Rasmussen; P. Klarskov; I. J. Christensen; Danish Prostatic Cance 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 1 views

Orchiectomy versus goserelin and flutami

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–-genitourinary group study 30853

✍ D. W. W. Newling; L. Denis; K. Vermeylen; European Organization for Research; Tr 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 603 KB

Short-term versus long-term addition of

Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer

✍ J. G. M. Klijn; H. J. De Voogt; U. E. Studer; F. H. Schröder; R. Sylvester; M. D 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 471 KB 👁 3 views

Treatment of newly diagnosed metastatic

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

✍ Gerald P. Murphy; Sunmolu Beckley; Mark F. Brady; T. Ming Chu; Jean B. Dekernion 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

by the National Prostatic Cancer Project randomized newly diagnosed metastatic prostate cancer patients to DES 1 mg orally three times daily or orchiectomy; or DES, 1 mg, three times daily, plus cyclophosphamide at 1 mg/m2 iv every three weeks, or cyclophosphamide 1 g/m2 iv every three weeks plus es

Intermittent chemotherapy in patients wi

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer : Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

✍ Tomasz M. Beer; Christopher W. Ryan; Peter M. Venner; Daniel P. Petrylak; Gurkam 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## BACKGROUND. Survival in patients with metastatic, chemotherapy‐naive, androgen‐independent prostate cancer (AIPC) is improved with 10 to 12 cycles of docetaxel‐containing chemotherapy but further management is undefined. In the current study, the authors examined retreatment with th